Expert Insights in Hemophilia Gene Therapy for Bleeding Disorders Awareness Month
In observance of Bleeding Disorders Awareness Month, held annually in March, catch up on some of the latest expert insights in gene therapies for hemophilia, which is among the most common of these disorders.
In recent months, CGTLive has interviewed multiple experts about the various gene therapies currently in development for the treatment of hemophilia A and hemophilia B, which are among the most commonly occurring bleeding disorders.
For Bleeding Disorders Awareness Month, observed annually in the month of March by the patient and clinician communities, the CGTLive team has gathered some of our latest interviews on hemophilia gene therapies below to offer expert insight on the therapeutic progress being made for these rare disorders.
Those featured include:
- Adam Cuker, MD, associate professor of medicine at the University of Pennsylvania
- Steven Pipe, MD, professor of pediatric hematology/oncology at CS Mott Children’s Hospital
- Brent Warner, president of gene therapy at Poseida Therapeutics
- Rigoberto Garcia, MPH, executive director of the Hemophilia Foundation Southern California
Click the respective slides below to watch each expert interview.
—————————————————
Considerations for Administering Hemoglobinopathy Gene Therapies From a Pharmacist’s Perspective
April 20th 2024Alexis Kuhn, PharmD, BCOP, a pediatric oncology pharmacist at Mayo Clinic, discussed the incorporation of the recently FDA-approved gene therapies for SCD and TDT into the work of pharmacists.
